Edition:
United Kingdom

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

37.69USD
18 Jan 2019
Change (% chg)

$0.88 (+2.39%)
Prev Close
$36.81
Open
$37.13
Day's High
$37.71
Day's Low
$36.67
Volume
2,428,800
Avg. Vol
1,939,200
52-wk High
$39.43
52-wk Low
$25.04

Latest Key Developments (Source: Significant Developments)

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC, EDWARDS LIFESCIENCES AGREE TO GLOBAL LITIGATION SETTLEMENT.BOSTON SCIENTIFIC CORP - ALL PATENT LITIGATION BETWEEN COMPANIES TO BE DISMISSED.BOSTON SCIENTIFIC CORP - EDWARDS HAS MADE A ONE-TIME PAYMENT TO BOSTON SCIENTIFIC OF $180 MILLION.BOSTON SCIENTIFIC CORP - ANY INJUNCTIONS CURRENTLY IN PLACE WILL BE LIFTED.BOSTON SCIENTIFIC CORP - NO FURTHER ROYALTIES WILL BE OWED BY EITHER PARTY UNDER AGREEMENT.BOSTON SCIENTIFIC CORP - CO & EDWARDS TO SETTLE ALL OUTSTANDING PATENT DISPUTES BETWEEN THEM.  Full Article

BTG Amends Co-Operation Agreement With Boston Scientific, Bidco
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - BTG PLC ::CO, BOSTON SCIENTIFIC, BIDCO ENTERED AMENDMENT TO CO-OPERATION AGREEMENT.CO-OPERATION AGREEMENT AMENDMENT TO EXTEND DATE BY WHICH SOME REGULATORY FILINGS MUST BE MADE IN SPAIN, GERMANY, OTHER JURISDICTIONS.  Full Article

Edwards Comments On U.S. Court Decision
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMMENTS ON U.S. COURT DECISION.COMMENTED TODAY ON A FEDERAL JURY'S DECISIONS IN PATENT LITIGATION BETWEEN EDWARDS AND BOSTON SCIENTIFIC.EDWARDS LIFESCIENCES-DOES NOT EXPECT TO PAY JURY AWARD SINCE U.S. PATENT AND TRADEMARK OFFICE DETERMINED ASSERTED CLAIMS OF '608 PATENT WERE INVALID.  Full Article

Boston Scientific Offers 840 pence/share For BTG Plc
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - BTG PLC ::BOSTON SCIENTIFIC BTG PLC - RECOMMENDED CASH OFFER FOR BTG PLC.SAYS UNDER TERMS OF ACQUISITION, BTG SHAREHOLDERS WILL BE ENTITLED TO RECEIVE: FOR EACH BTG SHARE: 840 PENCE IN CASH.SAYS OFFER PRICE VALUES ENTIRE ISSUED AND TO BE ISSUED ORDINARY SHARE CAPITAL OF BTG AT APPROXIMATELY £3.3 BILLION.SAYS BTG DIRECTORS INTEND TO RECOMMEND UNANIMOUSLY THAT BTG SHAREHOLDERS VOTE (OR PROCURE VOTING) IN FAVOUR.  Full Article

Boston Scientific Receives U.S. FDA Approval For The Eluvia Drug-Eluting Vascular Stent System
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM.  Full Article

Boston Scientific Announces Agreement To Acquire Augmenix, Inc.
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE AUGMENIX, INC..BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE AUGMENIX, INC..BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF AN UPFRONT CASH PAYMENT OF $500 MILLION, AND UP TO $100 MILLION FOR REACHING SALES-BASED MILESTONES..BOSTON SCIENTIFIC CORP - DEAL IS EXPECTED TO BE IMMATERIAL TO ADJUSTED EARNINGS PER SHARE IN 2018 AND 2019.BOSTON SCIENTIFIC CORP - TRANSACTION IS EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS PER SHARE IN 2020 AND INCREASINGLY ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE.  Full Article

Boston Scientific Corp Says Entered Into A $1 Bln Credit Agreement
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP - ON AUGUST 20, ENTERED INTO A $1.000 BILLION CREDIT AGREEMENT - SEC FILING.BOSTON SCIENTIFIC CORP - 2018 CREDIT AGREEMENT PROVIDES FOR A $1 BILLION 364 DAY TERM LOAN, MATURING ON AUGUST 19, 2019.BOSTON SCIENTIFIC-MAY INCREASE 2018 TERM LOAN COMMITMENT/GIVE NEW TERM LOAN FACILITY UNDER THE AGREEMENT IN AMOUNT NOT TO EXCEED $500 MILLION ON PRIOR NOTICE.  Full Article

Jana Partners LLC Dissolves Sole Share Stake In Dropbox, Takes In Wells Fargo And Cuts in Teva
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Jana Partners LLC::JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN DROPBOX INC - SEC FILING.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 1.1 MILLION SHARES IN WELLS FARGO & CO.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN BOSTON SCIENTIFIC CORP BY 33.6 PERCENT TO 3.1 MILLION SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN TIFFANY & CO BY 50.5 PERCENT TO 1.8 MILLION SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD BY 15.5 PERCENT TO 2.9 MILLION SPONSORED ADRS.JANA PARTNERS LLC - CHANGE IN HOLDINGS ARE AS OF JUNE 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF MARCH 31, 2018.  Full Article

Boston Scientific Announces Agreement To Buy VENITI
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE VENITI, INC..BOSTON SCIENTIFIC CORP - TRANSACTION PRICE FOR REMAINING STAKE CONSISTS OF $108 MILLION UP-FRONT CASH.BOSTON SCIENTIFIC CORP - ACQUISITION OF VENITI IS EXPECTED TO BE IMMATERIAL TO BOSTON SCIENTIFIC ADJUSTED EARNINGS PER SHARE (EPS) IN 2018 AND 2019.BOSTON SCIENTIFIC - DEAL PRICE FOR REMAINING STAKE ALSO CONSISTS OF UP TO $52 MILLION IN PAYMENTS CONTINGENT UPON U.S. FDA APPROVAL OF VICI STENT SYSTEM.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS FOR 2019 AND SUBSEQUENT YEARS, TRANSACTION IS EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE AS CASE MAY BE.BOSTON SCIENTIFIC - DEAL TO BE IMMATERIAL TO BOSTON SCIENTIFIC ADJUSTED EARNINGS PER SHARE (EPS) IN 2018 AND 2019, AND ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - FOR 2018 ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE ACCRETIVE DUE TO A ONE-TIME GAIN ON PRIOR INVESTMENT.  Full Article

Boston Scientific Agrees To Buy Claret Medical For $220 Mln In Up-Front Cash
Friday, 20 Jul 2018 

July 20 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE CLARET MEDICAL, INC..BOSTON SCIENTIFIC CORP - TRANSACTION PRICE CONSISTS OF $220 MILLION IN UP-FRONT CASH.BOSTON SCIENTIFIC CORP - DEAL IS EXPECTED TO BE IMMATERIAL TO ADJUSTED EARNINGS PER SHARE IN 2018.BOSTON SCIENTIFIC CORP - TRANSACTION PRICE ALSO CONSISTS OF A POTENTIAL REIMBURSEMENT-BASED MILESTONE PAYMENT OF UP TO $50 MILLION.BOSTON SCIENTIFIC CORP - ON GAAP BASIS, TRANSACTION IS EXPECTED TO BE LESS ACCRETIVE, OR MORE DILUTIVE AS CASE MAY BE.BOSTON SCIENTIFIC - DEAL IS EXPECTED TO BE ACCRETIVE IN 2019 & INCREASINGLY ACCRETIVE THEREAFTER.  Full Article

UPDATE 2-Edward Lifesciences pays Boston Scientific $180 mln to end patent row

Jan 15 Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.